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ABSTRACT 
Objective: The aim of the present work was to formulate and evaluate proniosomes of the poorly soluble drug, acyclovir incorporated in 
mucoadhesive polymeric films for improved buccal mucosal permeability of the drug while achieving prolonged release.  
Methods: Acyclovir was formulated as proniosomes using Span 60 and cholesterol. The prepared proniosomes were loaded into mucoadhesive 
polymeric films prepared with varying quantities of carbopol 934P and HPMC K15M. The proniosome incorporated films were evaluated for 
physicomechanical characters, mucoadhesion, swelling index, drug content, in vitro drug release and ex vivo permeation through porcine buccal mucosa.  
Results: Hydration of the proniosomes produced spherical vesicles or niosomes, which was confirmed by Scanning Electron Microscopy. The 
optimized formulation selected on the basis of vesicle size, entrapment efficiency PDI, Zetz potential and in vitro drug release was selected for 
incorporation into mucoadhesive polymeric films. All the films showed excellent physicomechanical characters. Formulations with higher 
proportions of carbopol produced slower in vitro drug release. The kinetics of release of drug from all the formulations appeared to be zero-order 
based on their regression coefficient values. Comparative evaluation of ex vivo permeation from niosomal and non-niosomal films indicated that the 
former demonstrated improved mucosal permeation and drug release was also sustained for the 8 h period.  
Conclusion: Mucoadhesive films impregnated with acyclovir loaded proniosomes could be a potential approach for buccal delivery of acyclovir for 
improving its absorption and bioavailability.  
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INTRODUCTION 
The oral therapy of acyclovir, an antiviral, has several limitations, 
such as poor oral bioavailability of only 15-30% due to its poor 
aqueous solubility. It has a short half-life of 2.5-3.3 h and therefore 
requires frequent dosing [1, 2]. Hence the chances of patient 
noncompliance with respect to adhering to the dosing schedule by 
the conventional oral route would be high. Acyclovir immediate-
release tablets and capsules are associated with cholinergic side 
effects like nausea, vomiting, dizziness, dyspepsia and acute renal 
failure [3]. Therefore, there is a need to improve the efficacy of 
acyclovir by improving absorption while reducing its toxicity. 
Several approaches have been investigated to enhance the oral 
bioavailability of acyclovir, such as prodrugs, self-emulsifying drug 
delivery systems and nanoemulsions to name a few [4, 5].  
An alternative approach to oral administration is the buccal mucosal 
delivery of acyclovir. Of all the transmucosal routes for the systemic 
delivery of drugs, administration through the buccal mucosa has 
some well-defined advantages. Besides its easy accessibility, 
excellent patient acceptance rate, the buccal mucosa is highly 
permeable and rich in blood supply with rapid recovery after 
damage or stress [6]. This route of drug administration is a means of 
avoiding first-pass metabolism and presystemic elimination in the 
gastrointestinal tract. Moreover, by the use of mucoadhesive 
controlled release buccal dosage forms, patient compliance can be 
improved by eliminating the need for frequent administration [7]. 
Several studies have been reported wherein acyclovir has been 
formulated as buccal tablets or films [8, 9]. However, the mucoadhesive 
buccal tablets of acyclovir currently in the market have been approved 
for the topical or local delivery of the drug in the oral cavity for the 
treatment of herpes labialis and is expected to be minimally absorbed 
through the oral mucosa. Thus the buccal mucosal delivery for systemic 
absorption of this drug is limited by its poor aqueous solubility and 
permeability. Generally, drugs which shows significant problems in 
absorption after oral administration due to limited solubility and poor 
permeability are likely to show similar problems even after buccal 
administration unless the drug is incorporated in the solubilized form 
first. One way of overcoming this problem is to use vesicular systems 
such as liposomes and niosomes, which can entrap both hydrophilic and 
hydrophobic drugs while their nanosize ensures permeation through the 
mucosa [10]. However, they are associated with physical and chemical 
instabilities due to aggregation, fusion or leakage upon storage, 
degradation of phospholipids by hydrolysis, and oxidation [11]. To avoid 
these problems, proniosomes, which are provesicular systems that are 
converted into niosomes upon hydration, can be an alternative. 
Proniosomes are actually surfactant coated water-soluble carriers in the 
form of a dry, free-flowing powder that on agitation with water, are 
converted to nonionic surfactant vesicles or niosomes. The use of 
proniosomes can solubilize the drug within the nonionic surfactant 
vesicles and improve its permeability through the buccal mucosa [12]. 
We hypothesize that the buccal absorption of acyclovir can be enhanced 
due to the combined effect of buccal and vesicular drug delivery system. 
Hence, the aim of our investigation was to formulate proniosomes of 
acyclovir which were incorporated into mucoadhesive buccal films 
fabricated from mucoadhesive polymers and investigate them for 
their efficacy in buccal permeation.  
MATERIALS AND METHODS 
Materials 
Acyclovir was a gift sample from Sanofi Aventis Goa, while span 60 
and cholesterol were procured from Loba Chemie Pvt Ltd Mumbai. 
Hydroxypropyl methylcellulose K15M (HPMC K15M) was obtained 
from Himedia Lab Pvt, Ltd, Mumbai and carbopol 934P was 
procured from Yarrow Chem Products, Mumbai. All other chemicals 
were of analytical grade. 
Preparation of proniosomes  
Span 60 and cholesterol are required for the preparation of the 
proniosomes. Span 60 is chosen among other spans because it is 
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reported to possess greater drug encapsulation efficiency owing to 
its long alkyl chain [13].  
Coacervation phase separation method was used in the preparation 
of proniosomes. Accurately weighed amounts of span 60 and 
cholesterol (the composition is given in table 1) were taken in a 
glass vial and acyclovir (50 mg) was added to the mixture. About 
0.16 ml of ethanol was admixed, and the vials were covered and 
warmed in a water bath at 50 ° C–65 °C until a clear solution was 
obtained. To this clear solution about 2 ml of the aqueous phase 
(distilled water) at 65 °C was added and warmed for 5 min. The 
resultant solution was allowed to cool until a white creamy gel of 
proniosomes was obtained. Obtained proniosomal system was 
lyophilized for stabilization. Prior to lyophilization, the dispersion 
was frozen at -30 °C for 1 d. The frozen sample was subjected to 
freeze drying for 6 h and immediately used for formulation [14]. 
  
Table 1: Composition of the acyclovir loaded proniosomes 
Formulation code Drug (mg) Span 60 (mg) Cholesterol (mg) 
N1 50 43 38.6 
N2 50 86 38.6 
N3 50 43 77.2 
N4 50 86 77.2 
N5 50 43 193 
N6 50 86 193 
 
Characterization of niosomes derived from acyclovir loaded 
proniosomes  
About 30 mg of prepared proniosomes from each formulation was 
taken in a glass tube, to which 10 ml of distilled water at 80◦ C was 
added and vortexed for about 15 min to get a niosomal dispersion. 
The formed niosomes were observed under an optical microscope at 
45X magnification [15]. 
The niosomal dispersion so obtained after hydration was characterized 
for vesicle size distribution, zeta potential, surface morphology by SEM, 
entrapment efficiency (EE) and in vitro release of acyclovir.  
For the entrapment efficiency, 3 ml of the niosomal dispersion was 
centrifuged at 18000 rpm for 15 min at 4 °C to separate the un-
entrapped drug. The supernatant layer was separated, of which 1 ml 
was withdrawn and diluted with Phosphate Buffer Saline (PBS) of 
pH 7.4 to 10 ml and the concentration of drug was determined using 
an UV spectrophotometer at 253 nm [16].  
The entrapment efficiency was calculated using the formula:  
% EE = (Ct - Cf)/Ct X 100   ………. (1) 
Where Ct = total drug incorporated and Cf 
The vesicle size distribution and zeta potential measurement was carried 
out using the Zetasizer nano ZS (Malvern Instruments Ltd., UK).  
= un-entrapped drug in 
the supernatant 
The surface morphology and vesicle shape of proniosomes before 
and after hydration was studied using SEM [17]. 
In vitro drug release from niosomes was determined using a dialysis 
bag of pore size, 0.22-0.45 micron and molecular weight cut-off 
(MWCO) of 14000-18000 (Himedia) [18]. Niosomal dispersion 
equivalent to 10 mg of drug was placed in the bag which was sealed 
and immersed in 200 ml of phosphate buffer of pH 7.4, maintained 
at temperature of 37±0.5 °C and stirred at 50 rpm on a magnetic 
stirrer. At suitable time intervals (15, 30, 60, 90, 120, 150, 180, 210, 
240, 270, 300, 330 and 360 min), samples were withdrawn from the 
dissolution medium and absorbance was measured using UV 
spectrophotometry at 253 nm.  
Preparation of buccal films 
Based on the results obtained from the characterization of the 
proniosomes, the optimal formulation was selected for 
incorporation into the buccal films.  
The mucoadhesive polymers HPMC K 15M and carbopol 934P were 
used in the ratio of 1:1, 1:3 and 3:1 and the buccal films were prepared 
by solvent casting. The required amounts of HPMC K 15M and 
carbapol 934P were dissolved in sufficient distilled water and stirred 
on a magnetic stirrer for 6 h. The pH of the polymeric solution was 
adjusted to neutral with triethanolamine (TEA). As a plasticizer, 
propylene glycol was mixed with the polymeric solution and the volume 
was made up to 25 ml using distilled water and the solution was kept 
overnight to remove air bubbles. Accurately weighed proniosome 
powder equivalent to 325 mg of drug was dispersed uniformly in the 
above solution and stirred slowly on a magnetic stirrer until a clear 
solution was obtained. The resultant solution was poured into circular 
glass moulds having a surface area of 70.84 cm2 and was allowed to dry 
at 40 °C in a temperature-controlled hot air oven. The top of the mould 
was covered with a funnel to permit controlled evaporation of water 
during the entire period of drying. The dried films were cut into circular 
dimension of 1.5 cm diameter and area of 1.766 cm2
 
, so that each film 
contained about 8 mg of Acyclovir. For the sake of comparison, films of 
the same composition were also prepared with acyclovir in the free 
form. In such films, the drug was incorporated by dissolving in 2 ml of 
dimethyl sulphoxide (DMSO) and then added to the polymeric solution 
before solvent casting. The obtained films were wrapped in aluminum 
foil and stored in a desiccators [19]. The composition of prepared buccal 
films is summarized in table 2. 
Table 2: Composition of casting solution for buccal films containing acyclovir without proniosomes 
Formulation F1 F2 F3 F4 F5 F6 
Acyclovir (mg) 325 325 325    
Weight of proniosomes equivalent to 325 mg of acyclovir (mg)    1100 1100 1100 
DMSO (ml) q. s  q. s q. s q. s  q. s q. s 
HPMC K 15M (mg) 100 50 150 100 50 150 
Carbapol (mg) 100 150 50 100 150 50 
Propylene glycol (ml) 1 1 1 1 1 1 
Water (ml)  25 25 25 25 25 25 
 
Evaluation of drug-loaded films 
Weight, thickness, surface pH and drug content  
The thickness of films was determined using a micrometer screw 
gauge and about 10 films were weighed individually. 
Drug content was determined by dissolving one film of 1.766 cm2 
area containing 8 mg of acyclovir in 100 ml of ethanol for 1 h with 
continuous stirring. From this solution, 10 ml was diluted to 50 ml 
using a simulated salivary fluid of pH 6.8 and the absorbance was 
measured using an UV spectrophotometer.  
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A desirable buccal film should be non-irritant to the oral mucosa and 
therefore, it is important to determine the surface pH when brought 
in contact with moisture. The film to be tested was placed in a petri 
dish and moistened with 0.5 ml of distilled water and kept for 30 s. 
The electrode of the pH meter was brought in contact with the 
surface of the formulation and allowed to equilibrate for 1 min and 
the pH was measured [20, 21].  
Mechanical properties of the films–folding endurance, tensile 
strength and percentage elongation  
Folding endurance was determined by repetitively folding a film at 
the same place until the film was broken when folded up to 300 
times. The number of times the films could be folded without 
breaking gives the value of the folding endurance [22].  
Tensile strength is the maximum stress applied to a point at which 
the film breaks. The Linus Bursting/tensile strength apparatus was 
used to determine the tensile strength. The pressure gauge was 
selected by turning a gauge selector switch, depending on the 
sample to be tested. Film strips free from air bubbles and other 
imperfections were cut into dimensions of 3 cm x 1 cm. One strip 
was placed on the diaphragm plate and the wheel on the top of the 
diaphragm plate was rotated till it fitted securely on the sample and 
did not rotate any further. The push-button was pressed till the 
sample broke. The tensile strength was directly read from the 
pressure gauge in Kg/cm2
The percentage elongation can be obtained by the following 
equation. 
. Measurements were run in triplicate for 
each film [23].  
% Elongation = (L1 - L2)/L2 x 100   ……. (2) 
Where L1 is the final length of each strip, and L2 
Swelling index 
is the initial length 
of each strip.  
The swelling index of the formulated films in the simulated salivary 
fluid was determined by a method documented by several 
researchers. A pre-weighed buccal film of area 1.766 cm2
% SI = (W
was placed 
in a stainless steel sieve (800 µm mesh) and immersed in a china 
dish containing 15 ml of simulated salivary medium. At regular 
intervals, the film was taken out, blotted with a tissue to remove 
excess moisture and then the film was reweighed. The increase in 
the weight of the film was noted in 15 min intervals until a constant 
weight was observed [24]. The swelling index was calculated using 
the equation below:  
t-W0)/W0 
Where SI is the swelling index, W
×100 …. (3) 
t  is the weight of the film at time t 
and W0
In vitro residence time 
 is the initial weight of the film. 
Using USP disintegration apparatus, the in vitro residence time was 
determined. The disintegration apparatus was filled with 900 ml of 
phosphate buffer of pH 6.8 maintained at 37±2 °C. Porcine buccal 
mucosal membrane of 3 cm length was glued to the surface of a glass 
slab, which was then fixed vertically in one of the tubes of the basket 
rack assembly. A film of 1.5 cm diameter was moistened on one side 
with a few drops of the phosphate buffer and was pressed briefly 
onto the mucosal membrane to bring about adhesion. The apparatus 
was switched on, to allow the glass slide with the attached mucosa to 
move up and down in the medium. The time required for complete 
erosion or detachment of the film from the mucosal surface was 
recorded [25]. 
Measurement of ex vivo mucoadhesive strength 
In order to prolong the residence time at the site of application and 
to provide prolonged drug release, satisfactory bioadhesion of the 
bioadhesive drug delivery system is essential. The tensile strength 
required to detach the bioadhesive films from the mucosal surface 
was taken as a measure of the bioadhesive performance. For the 
measurement of bioadhesive strength, several methods have been 
reported in the literature. In the present work, a specially designed 
or fabricated assembly based on published literature was used. For 
bioadhesion testing, a porcine check pouch was used as the model 
membrane. 
The basis of the bioadhesion test assembly is the working of a 
modified physical balance. A plastic cap (4 cm diameter) was fixed 
vertically to the left arm of the balance using a wire. To the lower 
surface of the cap, a buccal film of 1.5 cm diameter was attached 
using cyanoacrylate glue. A piece of freshly excised porcine buccal 
mucosa was attached to the upper end of a cylindrical Teflon block 
of 4 cm diameter with the mucosal side up. The block was fixed 
vertically onto the bottom centre of a 250 ml capacity beaker, which 
was positioned in such a way that the plastic cap was directly above 
the membrane-covered Teflon block with a gap of 0.5 cm between. 
The beaker was then filled with a sufficient buffer of pH 6.8 until the 
liquid level just skims the mucosal surface. The horizontal beam of 
the balance was balanced using a weight of 5 g on the right pan. 
For the measurement, the 5 g weight on the right pan was removed, 
allowing the left arm of the balance to lower, so that the cap with the 
film attached came in contact with the mucosa. A 20 g weight was 
placed on the cap to apply pressure on the mucosa for 3 min and 
then removed. Slowly, weights were added to the right pan, starting 
from the least, at 30 s intervals until the film was detached from the 
surface of the mucosa [26, 27]. The total weight at which the 
detachment occurred was noted and the bioadhesion force was 
calculated using the following equation:  
F = (WW 
F= bioadhesion force (kg/m/s





G = acceleration due to gravity (cm/s
= mass applied (g) 
2
A = surface area of the film (cm
) 
2
In vitro drug release studies from films 
) 
The buccal films were subjected to dissolution studies using the 
paddle-over-disc method with the USP Type II apparatus. A film of 
diameter 1.5 cm was cut and fixed to a glass slide using cyano-
acrylate glue. The glass slide was placed in the bottom of the 
dissolution vessel, which was later filled with 900 ml of simulated 
saliva (phosphate buffer, pH 6.8) maintained at 37±1 °C; the paddle 
was rotated at 50 rpm. Samples of dissolution medium were 
withdrawn at predetermined time intervals, filtered, and analyzed 
by UV Spectrophotometry after suitable dilution [28]. To maintain 
sink conditions the samples were replaced with equal volumes of 
fresh buffer. 
The drug release data were further subjected to kinetic analysis by 
fitting to different mathematical models such as zero order, first 
order and Korsmeyer-Peppas to predict the kinetics and release 
mechanism of the drug. 
Ex vivo permeation studies  
Porcine buccal mucosa for this study was procured fresh from the local 
slaughterhouse and the underlying connective tissue was separated and 
removed from the buccal mucosa membrane with surgical scissors, 
washed with phosphate buffer of pH 6.8 and used immediately [24].  
The ex vivo permeation studies of buccal films of Acyclovir were 
performed using the Franz Diffusion Cell. The porcine mucosa was 
clamped between the donor and receptor compartments. The 
receptor compartment contained 25 ml of phosphate buffer of pH 
7.4, which was stirred continuously at 100 rpm and maintained at 
37±0.5 °C to mimic physiological conditions. At appropriate time 
intervals, aliquots (1 ml) were withdrawn and replaced with an 
equal volume of fresh buffer to maintain sink conditions. The 
samples were filtered and analyzed by HPLC. 
Reconstitution of films for confirming the presence of niosomes 
Reconstitution of the prepared films was done to understand 
whether properties of proniosomes are affected by the film 
formation method.  
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The Acyclovir loaded films were reconstituted by taking three buccal 
films of 1 cm×1 cm diameter in a conical flask containing 50 ml 
distilled water. This was shaken and stirred for 1 h until a colloidal 
system was obtained. The reconstituted proniosomal dispersion was 
then examined under the optical microscope using 45 X 
magnification for the presence of vesicles. These results were 
compared with the corresponding data of the initial formulation 
(hydrated proniosomes) in terms of vesicle size, PDI and zeta 
potential. 
RESULTS AND DISCUSSION 
Proniosomes of Acyclovir were successfully prepared and were 
observed to be white, free-flowing powders.  
Characterization of niosomes derived from acyclovir loaded 
proniosomes 
Observation of the dispersion obtained after hydration of the 
proniosomes, under an optical microscope at 45x magnification, 
revealed spherical niosomes which were homogeneously dispersed. 
The drug entrapment efficiency (EE) was observed to be in the range 
of 13.63-53.76 % as shown in table 3. Significant increase in 
entrapment efficiency was observed when the concentration of span 
60 was increased, which is due to an increase in the formation of 
niosomes as a consequence. At low concentrations of cholesterol, the 
encapsulation efficiency was also found to be low and initially 
increases with increasing concentrations of cholesterol. This is 
because cholesterol is the key element for improving the stability of 
the bilayer, increasing its hydrophobicity and reducing its 
permeability to the entrapped drug. But when the cholesterol 
content exceeded beyond a particular point, the entrapment 
efficiency decreased. This observation is attributed to the fact that 
cholesterol beyond a certain level disturbs the regular bilayer 
structure of proniosomes resulting in the expulsion of the drug from 
the bilayer due to overcrowding, during the vesicle formation [29]. 
Among all the formulations, N4 was found to have maximum 
entrapment efficiency (53.76 %), indicating that its composition was 
optimal. 
The results for vesicle size, PDI and Zeta potential are displayed in 
table 3. Vesicle size is important for stability and can influence drug 
encapsulation, membrane permeation as well as cellular uptake and 
bioavailability. The vesicle size for all formulations was less than a 
micron with the exception of N1 and N2. The highly negative values 
for Zeta potential indicate high physical stability of the dispersions 
due to electrostatic repulsion between particles. The PDI values 
indicate homogeneity of the dispersions of all formulations.  
SEM studies showed that the acyclovir proniosomes were irregularly 
shaped particles with a rough surface. Morphology of proniosomes 
of acyclovir before hydration was shown in fig. 1(A). After hydration, 
the resulting niosomes were spherical and uniform and the surfaces 
were found to be smooth as shown in fig. 1(B). 
 
 
Fig. 1: A) SEM of proniosomes before hydration B) SEM of proniosomes after hydration 
 
In vitro drug release studies using dialysis bag, indicate that the 
formulation N4 showed maximum drug release (74.09 %) at the end 
of 6 h when compared to other formulations. Drug release was 
markedly decreased in N5 and N6 since the increased cholesterol 
content could reduce the gel to the liquid phase transition of 
niosomal bilayers leading to decrease in the fluidity of the niosomal 
membrane and enhancing its rigidity and thereby decreasing its 
permeability and release rate [30]. The results for drug release from 
the niosomes is shown in table 3. 
On the basis of results obtained from the characterization studies of 
niosomes, N4 was considered as the optimal formulation and was 
selected for incorporation into buccal films. 
 
Table 3: Data for particle size, PDI, zeta potential, EE and maximum % CDR for all niosome formulations 
Product code Vesicle size (nm) PDI Zeta potential (mV) EE (%)* Maximum CDR (%)* at 6 h 
N1 1045 0.251 -46.82 28.56±1.12 64.74±0.12 
N2 1024 0.316 -31.48 34.76±0.74 59.50±0.14 
N3 972 0.332 -35.12 46.32±1.31 61.73±0.11 
N4 962 0.234 -42.40 53.76±1.32 74.09±0.14 
N5 836 0.253 -37.19 13.63±1.54 44.93±0.10 
N6 845 0.205 -33.12 19.54±1.32 42.00±0.15 
EE–Entrapment efficiency; CDR–Cumulative drug released; *Average of 3 measurements with standard deviation 
 
Preparation of buccal films 
Buccal films were prepared using HPMC K15M and carbopol 934P 
and a comparison was made between buccal films containing free 
drug and buccal films incorporated with proniosomes.  
The films prepared were then evaluated for various physico-
mechanical properties. The films from all the batches were smooth 
and flexible without any signs of roughness, air bubbles and other 
deformities. Films with proniosomes (F4, F5, and F6) were 
comparatively more smooth and translucent than films with free 
drug (F1, F2, and F3). This may be because in case of films with 
proniosomes, the drug was entrapped within the niosome vesicles; 
therefore the drug remained solubilized and did not precipitate. But 
films in which the drug was directly added are comparatively 
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whitish because of poor solubility of the drug, which may have 
caused some degree of precipitation on the surface of the film.  
Evaluation of drug-loaded films 
Weight, thickness, drug content and surface pH  
The data for weight and thickness determined for all formulations is 
given in table 4. The weights of films with higher polymer content 
were found to be greater. It was observed that the thickness of all 
film samples was uniform in each formulation. The average 
thickness was found to be in the range of 0.221 to 0.311 mm. The 
films with larger amounts of HPMC K 15M were slightly thicker. The 
percentage drug content of the niosomal formulation was found to 
be in the range of 93-95 % as shown in table 4, whereas for the non-
niosomal films, it was approximately 90-93%. The lower drug 
content in formulations, F1-F3 could be due to loss of the 
precipitated form of the drug during the drying of the films. 
In order to confirm the ideal pH for the application of buccal films 
orally, the pH of the buccal films was measured to avoid any 
irritation to the oral mucosa. It was observed that the surface pH of 
the films was close to the buccal pH of 6.8 and this means that they 
may have less potential to irritate the buccal mucosa and hence 
more comfortable. The results of surface pH are displayed in table 4. 
 
Table 4: Data of weight, film thickness, surface pH, and drug content for film formulations 
Formulation code Weight (mg) Thickness (mm)# Surface pH# Drug content uniformity (%)* * 
F1 22.62±1.14 0.234±0.1 6.74±0.1 93.12±1.23 
F2 27.46±1.16 0.229±0.27 6.66±0.3 90.97±0.94 
F3 29.92±1.12 0.301±0.23 6.73±0.2 92.08±1.25 
F4 23.75±0.93 0.221±0.25 6.70±0.4 93.72±0.826 
F5 25.97±1.19 0.231±0.29 6.78±0.5 94.75±0.903 
F6 30.12±1.15 0.311±0.003 6.52±0.8 95.78±1.321 
 *Mean of 3 determinations±SD #Mean of 5 determinations±SD 
 
Mechanical properties of the films–folding endurance, tensile 
strength and percentage elongation  
The ability of the films to sustain mechanical handling as well as have 
adequate flexibility when used in the oral cavity, was evaluated by 
determining folding endurance. The films containing free drug showed 
folding endurance (table 5) less than 300 (F1, F2, F3), probably due to 
the undissolved drug, which produced a non-homogenous polymer 
mass. On the other hand, the films with the niosomal form of the drug 
produced a folding endurance of 300 and more (F4, F5, F6). The drug 
being in the solubilized form in the niosomes, produced a homogenous 
polymer mass which yielded more flexible films. Such films are better 
able to conform to the contours of the buccal mucosa during 
application without cracking or breaking and therefore with lesser 
chances of mechanical irritation or drug loss. 
The tensile strength gives an indication of the strength and elasticity 
of the film. The results for the measured tensile strength and 
percentage elongation of all the formulations are shown in table 5. It 
is observed that the film formulations F3 and F6 demonstrated the 
highest tensile strength and the least percentage elongation. These 
formulations possessed the lowest content of carbopol 934P, which 
is known to be a soft polymer that increases the softness, flexibility 
and elasticity of the film but decreases tensile strength [31]. On the 
other hand film formulations with lower content of HPMC resulted 
in lower tensile strength but higher percentage elongation. A 
suitable buccal film should have high tensile strength and 
percentage elongation, which means that the proportions of HPMC 
and carbopol need to be balanced to yield films which are flexible 
and comfortable to wear but have sufficient strength to withstand 
mechanical handling.  
Swelling index 
The ability of the water-soluble polymer to take up water upon 
hydration can be determined using the swelling index. Swelling 
property of polymer is an important parameter which is responsible 
for establishing intimate contact of the film with the buccal mucosal 
surface through the formation of weak bonds and ultimately its 
bioadhesion [32]. Percentage swelling index of all the formulations 
was found to be in the range of 65.87-75.87% (table 5). Formulation 
F2 and F5 showed higher values of swelling index due to the 
presence of higher concentrations of carbopol 934P. This may be 
attributed due to the high water uptake capacity of carbopol 934P 
[33]. The water permeability increased as the quantity of carbopol 
934P increased in the film. The presence of the drug in the free or 
niosomal form did not have a significant effect on the percentage 
swelling index among the formulations. 
 
Table 5: Data for tensile strength measurement, percentage elongation, folding endurance and percentage swelling index for buccal films 
of acyclovir 
Formulation code Tensile strength (kg/cm2) Percentage elongation* Folding endurance* Percentage swelling index* * 
F1 2.3±0.2 37.8±0.1 236 65.87±0.12 
F2 2.0±0.4 43.1±0.4 254 75.87±0.02 
F3 2.8±0.1 35.9±0.2 245 69.76±1.23 
F4 2.9±0.4 40.1±0.4 >300 66.98±0.43 
F5 2.5±0.1 45.7±0.2 >300 73.87±1.43 
F6 3.2±0.2 37.8±0.4 >300 68.91±0.02 
*
 
Mean of 3 determinations±SD 
In vitro residence time 
Residence time is the time taken for the films to detach or erode 
completely from the mucosa and will therefore determine how long 
the film will remain in the oral cavity after administration. Since the 
mucoadhesive polymer in the composition is responsible for the 
adhesive interaction of the film with the mucosa, the concentrations 
of the former play an important role in the retention time of the 
latter on the mucosal surface. Both HPMC K15M and Carbopol 934P 
are classified as mucoadhesive polymers of which the latter is 
reported to have greater mucoadhesive properties. The carboxylic 
groups in carbopols are capable of forming strong hydrogen bonds 
with the oligosaccharide chains present in the mucin [34].  
It was observed that as the amount of carbopol in the film 
composition increased, there was an increase in the mucoadhesion 
time; therefore, F2 and F5 exhibited the longest residence time 
among the non-niosomal and niosomal films, respectively. As shown 
in fig. 2, the residence time was slightly lesser for the non-niosomal 
or free drug-containing films as compared to that of niosomal films. 
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Fig. 2: Comparison of in vitro residence time of all formulations 
 
Measurement of ex vivo mucoadhesive strength 
In order to increase the residence time at the site of application and 
to provide prolonged drug release, satisfactory bioadhesion of 
bioadhesive drug delivery is essential. As described earlier, although 
both carbopol 934P and HPMC K15M are mucoadhesive, the 
contribution of the former to the total mucoadhesive strength of the 
film onto the porcine mucosa appears to be greater. As fig. 3 clearly 
indicates, the mucoadhesive strength of films increases with 
increasing concentrations of carbopol. Like the in vitro residence 
time, the measured mucoadhesive strength appeared to be greater 
for the niosomal films as compared to the non-niosomal films. 
 
 
Fig. 3: Comparison of ex vivo mucoadhesive strength of all formulations 
 
In vitro drug release studies from films 
Fig. 4, 5 and 6 compare the in vitro drug release profiles from the 
noisome incorporated films with their corresponding non-niosomal 
films. Formulations with free acyclovir showed lesser release as 
compared to the proniosome incorporated films. As described 
earlier, the drug in the former formulations was present in the 
precipitated form due to decreased solubility in the polymer mass 
during the drying of the films. This form of the drug was also not 
very soluble in the release medium. On the other hand, the niosomal 
films, F4-F6 showed better release since acyclovir was solubilized in 
the polymer mass by virtue of the niosomes formed by the hydration 
of the proniosomes during the preparation of films. In the case of all 
the formulations (F1-F6), irrespective of the presence or absence of 
proniosomes, the drug release profiles indicate that as the ratio of 
carbopol 9334P to HPMC in the film composition increases, there is 
a decline in the rate of drug release as exhibited by F2 and F5. This 
may be due to the fact that higher proportions of carbopol tend to 
increase the swelling effect of the films upon hydration and 
consequently produce a thicker diffusional barrier to the release of 
the drug. This effect of carbopol concentrations on drug release was 
observed from the formulations for both niosomal and non-niosomal 
films. The formulation with a higher proportion of HPMC has 
demonstrated greater drug release at the end of the 8 h. The 
maximum percentage drug release (93.2%) was recorded from F6, 
which had the lowest concentration of carbopol and the highest 
concentration of HPMC among the niosomal films. All formulations 
exhibited sustained release of acyclovir during the 8 h period. 
 
 
Fig. 4: In vitro drug release profiles from F1 and F4 
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Fig. 5: In vitro drug release profiles from F2 and F5 
 
 
Fig. 6: In vitro drug permeation profiles from F3 and F6 
 
The data from kinetic analysis using various models is given in table 6. 
Based on the regression coefficient value (R2
  
) values determined for 
different models, it is evident that drug release from the formulations 
followed zero-order kinetics. The value of release exponent “n” obtained 
by applying Korsmeyer-peppas equation for all the formulations was 
greater than 0.5 and less than 1, hence the mechanism of drug release 
from these formulations followed anomalous or non–Fickian release, 
that is a combination of diffusion and polymer surface erosion [35, 36]. 
Table 6: Data for kinetic analysis of drug permeation from films 
Formulation code Zero-order R First-order R2 Korsmeyer-peppas 2 
R n 2 
F1 0.9243 0.9037 0.9673 0.6741 
F2 0.9261 0.9430 0.9845 0.6914 
F3 0.9550 0.9507 0.9897 0.7244 
F4 0.9858 0.9107 0.9723 0.7256 
F5 0.9913 0.8768 0.9725 0.7805 
F6 0.9775 0.7445 0.9822 0.7595 
R2
 
–Regression coefficient; n–Release exponent 
Ex vivo permeation studies  
On the basis of the mechanical film properties, drug content, 
mucoadhesive strength, in vitro residence time and in vitro drug 
release data, formulation F5 was considered optimum and was 
selected for ex vivo permeation studies using porcine buccal mucosa. 
Porcine buccal mucosa was selected as the membrane model for the 
permeation studies since it is similar to human buccal mucosa in 
structural characteristics and permeability. On comparing the drug 
permaetion profiles of niosomal film F5 and its corresponding free 
acyclovir containing film, F2, the drug permeation was found to be 
higher from the former. The maximum percentage of drug permeated 
from F5 was 80.24 %, whereas, from F2, it is only 59.72 %. The 
comparison of their drug permeation profiles is shown in fig. 7. This 
was further confirmed by the determination of permeation flux of 
acyclovir through the porcine mucosal membrane from F2 and F5. For 
this purpose, the amount of drug permeated through the membrane in 
8 h was determined and plotted against time. Using regression 
analysis the slope of the linear portion of the plot was calculated and 
divided by the mucosal surface area to give the permeation flux. The 
steady-state permeability coefficient was calculated by dividing the 
permeation flux by the donor phase drug concentration [37,38]. The 
permeation flux of acyclovir from F2 and F5 was 11.27 µg/cm2/h and 
13.97 µg/cm2
From the above results it can be concluded that our objective of 
improving the permeation of acyclovir by incoparating in proniosomes 
and further embedding into a buccal films was achieved. 
/h, respectively. The permeability coefficient of the drug 
from F2 and F5 was calculated to be 0.00141 and 0.00175 
respectively. This comparison reveals that the incorporation of 
acyclovir into proniosomes has improved its permeation through the 
membrane as compared to free acyclovir films. 
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Fig. 7: Ex vitro drug permeation profiles from F2 and F5 
 
Reconstitution of films for confirming the presence of niosomes 
Formulations F4, F5 and F6 were reconstituted as per the method 
described earlier. On dissolution of the film, a clear solution was 
formed, which when observed under the optical microscope, showed 
intact vesicles. These results concluded that the vesicle size and shape 
have been retained during the film formation. The measured vesicle 
size, PDI and zeta potential of the reconstituted film were comparable 
to that of the initial dispersion obtained by hydrating the proniosomes. 
Therefore, it can be concluded that the niosomes retained their 
properties even after film formation and the process of incorporation 
into the polymer mass did not affect the integrity of the proniosomes. 
CONCLUSION 
Proniosomes of acyclovir were successfully formulated by using 
Span 60 and cholesterol, which were then loaded into mucoadhesive 
buccal films formulated from various ratios of carbopol 934P and 
HPMC K 15M. The present study has established the fact that it was 
possible to formulate stable and uniform mucoadhesive buccal films 
from poorly soluble drugs such as acyclovir. The use of proniosomes 
helped to avoid some of the inherent problems associated with the 
preparation and use of niosomes or liposomes. Further, this 
investigation revealed that it was possible to improve permeation of 
acyclovir through the buccal mucosa when proniosomes of the drug 
was incorporated into the mucoadhesive films, which could 
potentially improve the bioavailability of this drug. Thus the dose of 
the drug could be reduced, and therefore the toxicity associated with 
it, while improving patient compliance. Hence these films could be 
promising formulations in the buccal delivery of acyclovir for the 
treatment of viral infections.  
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